Human Aging and in Vivo Noradrenergic System

Human Aging and in Vivo Noradrenergic System

Publication date: May 08, 2019

The main goal of this research proposal is to provide, for the first time in humans, a wider understanding of the role of the noradrenergic system both in health and illness (Parkinson’s disease) through the use of a newly developed radiotracer (11Carbon [11C]Yohimbine) visualizing alpha-2 (?2) adrenergic receptors (AR) combined with cutting-edge technology, the hybrid positron emission tomography (PET)/magnetic resonance imaging (MRI) scanner. The secondary aim of this study will be to determine whether the expected age- and Parkinson’s disease (PD)-related changes in the noradrenergic system are paralleled by changes in neuropsychological performances (such as cognitive, motor and/or olfactory abilities).

Concepts Keywords
Adrenergic Receptors Magnetic resonance imaging
Alcohol Embedded metal objects
Cognitive Sensitive head trauma
Consciousness Disease
Head Trauma Radiation
Hybrid Drug therapies
Idiopathic Medical imaging
Informed Consent Medicine
Ionizing Radiation Medical physics
Lyon Neuroimaging
Magnetic Resonance Imaging Tomography
Millisievert Positron emission tomography
MRI Magnetic resonance imaging
MRI Scanner Applied sciences
Neuropsychological Positron Corporation
Noradrenergic Alpha
Olfactory Radiation
Parkinson Magnetic resonance imaging
PET Tomography
Positron Emission Tomography MRI
Radiotracer
Social Security
Somatic
Substance Abuse

Semantics

Type Source Name
disease MESH Aging
pathway BSID Aging
drug DRUGBANK Yohimbine
gene UNIPROT CYREN
gene UNIPROT CD5L
gene UNIPROT CD69
gene UNIPROT DNMT1
disease MESH loss of consciousness
gene UNIPROT NR4A2
gene UNIPROT ALG3
drug DRUGBANK Ethanol
disease MESH substance abuse
disease DOID substance abuse
disease MESH contraindications
disease MESH Parkinson Disease
disease DOID Parkinson Disease

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *